Galcanezumab

The efficacy of galcanezumab in migraine prevention and impact on premonitory symptoms and triggers 14:33
The efficacy of galcanezumab in migraine prevention and impact on premonitory symptoms and triggers
Sait Ashina • 17 May 2023
REGAIN trial of galcanezumab in chronic migraine 1:18
REGAIN trial of galcanezumab in chronic migraine
Uwe Reuter • 25 Jun 2022
The current regulatory status of PROMs for clinical trials in migraine 1:59
The current regulatory status of PROMs for clinical trials in migraine
Richard Lipton • 13 Jun 2022
Is the CGRP ligand or receptor a better target in migraine? 2:52
Is the CGRP ligand or receptor a better target in migraine?
Oved Daniel • 24 Sep 2021
Approval of anti-CGRP monoclonal antibodies for migraine in Japan 1:47
Approval of anti-CGRP monoclonal antibodies for migraine in Japan
Koichi Hirata • 10 Sep 2021
Progress in headache treatment & novel therapeutic targets 1:44
Progress in headache treatment & novel therapeutic targets
Anna Andreou • 10 Sep 2021
Total pain burden reduced by galcanezumab in treatment-resistant migraine 6:19
Total pain burden reduced by galcanezumab in treatment-resistant migraine
Jessica Ailani • 21 Jun 2021
Upcoming treatments for migraine: zavegepant, rimegepant and atogepant 3:02
Upcoming treatments for migraine: zavegepant, rimegepant and atogepant
Jessica Ailani • 18 Apr 2021
Therapeutic landscape for cluster headache 11:31
Therapeutic landscape for cluster headache
Stewart Tepper • 24 May 2020
CGRP monoclonal antibodies & migraine management during COVID-19 pandemic 20:54
CGRP monoclonal antibodies & migraine management during COVID-19 pandemic
Stewart Tepper • 24 May 2020
CONQUER: galcanezumab in treatment-resistant migraine 9:29
CONQUER: galcanezumab in treatment-resistant migraine
Stewart Tepper • 24 May 2020
Efficacy of galcanezumab in older patients with migraine 0:59
Efficacy of galcanezumab in older patients with migraine
Dagny Holle-Lee • 20 May 2020
The content of VJNeurology is intended for healthcare professionals